Exagen Inc. (NASDAQ: XGN) reported Q3 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $12.5 million versus the consensus estimate of $13.57 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.